Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients
Latest Information Update: 16 Jan 2023
Price :
$35 *
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 11 Jan 2023 Status changed from recruiting to completed.
- 20 May 2022 Planned End Date changed from 30 Nov 2022 to 31 Dec 2022.
- 20 May 2022 Planned primary completion date changed from 30 Nov 2022 to 31 Dec 2022.